search

Active clinical trials for "Syndrome"

Results 5441-5450 of 9759

Effect of Brown Rice on the Risk Factors for Metabolic Syndrome

Metabolic Syndrome

The purpose of the study is to determine the effect of consumption of brown rice on the risk factors of metabolic syndrome (MetS) as compared to consumption of white rice. Brown and white rice will be provided in the form of rice cakes and 100g will be consumed per day for 5 weeks each. The investigators hypothesize that brown rice will have beneficial effects as it is rich in fiber and also phytochemicals.

Completed28 enrollment criteria

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant...

Diarrhea-predominant Irritable Bowel Syndrome

To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel syndrome (D-IBS).

Completed11 enrollment criteria

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared...

Non-ST or ST Elevation Acute Coronary Syndromes

The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.

Completed9 enrollment criteria

Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)

This study is being done to see how safe an investigational drug is and test how well it will work to help people with refractory/relapsed myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).

Completed19 enrollment criteria

Treatment Trial of Subclinical Hypothyroidism in Down Syndrome

Down SyndromeSubclinical Hypothyroidism

The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.

Completed11 enrollment criteria

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic...

Acute Myeloid LeukemiaAlkylating Agent-Related Acute Myeloid Leukemia3 more

This phase I trial studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome or acute myeloid leukemia. DEC-205-NY-ESO-1 fusion protein, called CDX-1401, is a full length NY-ESO-1 protein sequence fused to a monoclonal antibody against DEC-205, a surface marker present on many immune stimulatory cells. This drug is given with another substance called PolyICLC, which acts to provoke any immune stimulatory cells which encounter the NY-ESO-1-DEC-205 fusion protein to produce an immune response signal against NY-ESO-1. Immune cells which have thus been primed to react against NY-ESO-1 may then attack myelodysplastic or leukemic cells which express NY-ESO-1 after exposure to the drug decitabine. The chemotherapy drug decitabine is thought to act in several different ways, first, it may directly kill cancer cells, and secondly, the drug can cause cancer cells to re-express genes that are turned off by the cancer, including the gene for NY-ESO-1. Giving DEC-205/NY-ESO-1 fusion protein (CDX-1401) and polyICLC together with decitabine may allow the immune system to more effectively recognize cancer cells and kill them.

Completed27 enrollment criteria

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

The study will enroll low risk MDS patients who need red blood cell transfusions and who are refractory to or are not using erythropoiesis-stimulating agents. The purpose of the study is to determine whether oral rigosertib treatment results in hematological improvements according to the 2006 International Working Group criteria in these patients. The study will also record any side effects that may occur during the study.

Completed30 enrollment criteria

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Rett Syndrome

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.

Completed25 enrollment criteria

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration...

Sanfilippo Syndrome

Sanfilippo syndrome Type A, or Mucopolysaccharidosis (MPS) IIIA, is a rare lysosomal storage disease caused by deficiency of the enzyme heparan N-sulfatase (sulfamidase). In the absence of this enzyme, there is an accumulation of the glycosaminoglycan, heparan sulfate, resulting in progressive neurodegeneration. Symptoms are usually first noted in the 1st or 2nd year of life, although definitive diagnosis is often delayed, with an average age of diagnosis of 4.5 years. The disease is characterized by developmental delays initially, followed by neurological developmental arrest, then regression. These developmental deficits are typically associated with severe behavioral disturbances. Patients have a significantly reduced lifespan, with few surviving beyond the 2nd or 3rd decade. The purpose of this study is to evaluate the safety and efficacy of recombinant human heparan-N-sulfatase (rhHNS) in pediatric patients with Early Stage Mucopolysaccharidosis Type III A Disease.

Completed21 enrollment criteria

Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel...

Non-constipation Irritable Bowel Syndrome

The purpose of this study is to determine the efficacy and safety of different doses of SKI3246 compared with placebo in the treatment of patients with irritable bowel syndrome with non-constipation.

Completed8 enrollment criteria
1...544545546...976

Need Help? Contact our team!


We'll reach out to this number within 24 hrs